These cells resistant to traditional therapies are more susceptible to RSL3 when compared with those non-resistant cells in melanoma, prostate cancer, and sarcomas13,14.Inhibition of GPX4 significantly enhanced the anti-tumor effect of lapatininb via inducing ferroptosis in lapatinib-resistant lung cancer cells15. Here, GPX4 is linked to neoplasm.